Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : NVO save search
Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis
Published: 2023-10-10 (Crawled : 21:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 3.75%
H: 2.82%
C: 2.42%
kidney
The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight
Published: 2023-10-09 (Crawled : 21:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 0.09%
H: 1.41%
C: 0.94%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.67%
H: 0.56%
C: -0.01%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.48%
H: 1.39%
C: 0.51%
ALPN | $64.535 0.16% 0.16% 4M
|
Health Technology
|
| O: -1.07%
H: 0.0%
C: -6.9%
bleeding disease market
Novo Nordisk A/S - share repurchase programme
Published: 2023-10-09 (Crawled : 11:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -1.07%
H: 1.15%
C: 1.02%
repurchase
Global Diet Pills Market Research Report 2023: Market is Expected to Reach $ 2.47 Billion in 2027 - Focus on Xenical, Qsymia, Saxenda, Diethylpropion, Liraglutide, and Phentermine
Published: 2023-10-05 (Crawled : 10:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.08%
H: 1.44%
C: 1.15%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.39%
H: 0.72%
C: 0.61%
report expected reach research global market
Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study
Published: 2023-10-04 (Crawled : 13:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 1.88%
H: 0.59%
C: -0.44%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.39%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 6.22%
H: 1.26%
C: -6.19%
ozempic obesity study
Notice of Extraordinary General Meeting in Orexo AB (publ)
Published: 2023-10-03 (Crawled : 09:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -2.4%
H: 0.22%
C: -2.03%
meeting
FDA approves Rivfloza™ for children ≥9 years old and adults living with primary hyperoxaluria type 1 (PH1), a rare genetic condition
Published: 2023-10-02 (Crawled : 17:00) - biospace.com/
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.85%
H: 3.13%
C: 1.81%
fda rare children genetic living
Novo Nordisk A/S - share repurchase programme
Published: 2023-10-02 (Crawled : 12:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.85%
H: 3.13%
C: 1.81%
repurchase
Global Bleeding Disorders Market Set to Surge, Expected to Reach $25.97 Billion by 2032 with a 6.6% CAGR
Published: 2023-09-27 (Crawled : 02:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.56%
H: 0.06%
C: -0.62%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.51%
H: 0.62%
C: 0.42%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
GRFS | News | $6.29 -3.82% -3.97% 1.2M
|
Health Technology
|
| O: -0.22%
H: 1.09%
C: -0.55%
bleeding expected reach disorders global set market
Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight
Published: 2023-09-26 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.51%
H: 0.62%
C: 0.42%
BSX | $67.33 -0.13% -0.31% 7M
|
Health Technology
|
| O: -0.09%
H: 0.72%
C: -1.29%
SLN | $22.75 3.32% 3.21% 310K
|
Health Technology
|
| O: -1.3%
H: 2.44%
C: -1.42%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
MESO | $5.19 1.57% 1.54% 230K
|
Health Technology
|
| O: 3.25%
H: 1.57%
C: -3.15%
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.99%
H: 2.09%
C: 0.83%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 1.0%
H: 0.69%
C: -1.01%
disease cardiovascular growth market
Acesion Pharma Closes Oversubscribed €45M Series B Financing Round to Advance Development of Novel Therapy for Atrial Fibrillation
Published: 2023-09-26 (Crawled : 06:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 1.81%
H: 0.2%
C: -1.07%
pharma series therapy
Novo Nordisk A/S - share repurchase programme
Published: 2023-09-25 (Crawled : 15:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.44%
H: 0.33%
C: 0.25%
repurchase
Valo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence
Published: 2023-09-25 (Crawled : 12:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.44%
H: 0.33%
C: 0.25%
health
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
Published: 2023-09-21 (Crawled : 13:30) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -1.92%
H: 0.61%
C: -1.74%
acquisition
Novo Nordisk and UNICEF to extend joint initiative to prevent global childhood obesity
Published: 2023-09-20 (Crawled : 19:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -1.92%
H: 0.61%
C: -1.74%
obesity initiative global
OnKure Therapeutics Appoints Ann Howell, Pharm.D., as Vice President of Regulatory Affairs
Published: 2023-09-20 (Crawled : 17:00) - biospace.com/
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 1.26%
H: 1.82%
C: 0.03%
therapeutics
Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility
Published: 2023-09-19 (Crawled : 17:00) - aspenpharma.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.56%
H: 1.1%
C: 0.8%
contract agreement insulin
EIFO and Novo Holdings lead €14M round in Power-to-Peroxide pioneer HPNow
Published: 2023-09-19 (Crawled : 06:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.56%
H: 1.1%
C: 0.8%
Novo Nordisk A/S - share repurchase programme
Published: 2023-09-18 (Crawled : 12:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -2.63%
H: 1.75%
C: 0.64%
repurchase
Glentra Capital, a new energy transition investment firm backed by large Danish investors, announces first close of EUR 443 million
Published: 2023-09-14 (Crawled : 06:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 0.92%
H: 0.68%
C: -0.79%
energy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.